Last Updated: May 10, 2026

Patent: 5,849,704


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,849,704
Title:Pharmaceutical formulation
Abstract:A pharmaceutical preparation comprising a growth hormone and histidine or a derivative of histidine as additive or buffering substance shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved preparation at ambient temperature. Crystallization of growth hormone in the presence of histidine or a derivative thereof gives rise to a higher yield of crystals having a higher purity than known methods.
Inventor(s):Hans Holmegaard S.o slashed.rensen, Lars Skriver, Annie Rassing Hoelgaard
Assignee:Novo Nordisk Health Care AG
Application Number:US08/458,386
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

United States Patent 5,849,704: What the Claims Cover and How the US Landscape Looks

Are the claims for US 5,849,704 provided?

No. The request includes “The claims are:” but does not include the claim text. Without the actual claim language, a complete and accurate claim-by-claim analysis cannot be produced.

What can be concluded about the patent landscape without the claims?

No complete and accurate landscape assessment can be produced because the scope of protection depends on independent claim elements and claim construction risks (e.g., claim breadth, functional limitations, dependent claim narrowing, and potential design-around entry points). The landscape also depends on the specific asserted claim features, which are not stated.

What is the status of US 5,849,704 in the public record?

No. The patent’s bibliographic details (assignee, filing date, title, inventor list), claim set, prosecution history, and cited references are not provided in the prompt, so the record cannot be verified and mapped to the active landscape in a way that meets a “high-stakes R&D or investment” standard.

Can a critical analysis of novelty, obviousness, and enforceability be completed?

No. Those determinations require the actual claim elements and at least the following: the closest prior art cited against the application, the examiner’s reasoning, and the claim construction context. None of those are included.


Key Takeaways

  • The prompt does not include the claim text for US 5,849,704, so a complete claim-scope analysis cannot be produced.
  • A defensible US patent landscape critique depends on claim elements and the specific scope they define. Those elements are missing.
  • A novelty, obviousness, and enforceability assessment cannot be completed without claim language and prosecution/citation record.

FAQs

  1. What is required to analyze US 5,849,704 claims critically?
    The full claim text (at least the independent claims), plus the specification passages that define key terms.

  2. Why does landscape analysis require claim language?
    Because enforceable scope and design-around feasibility track claim elements, not just the patent title or general subject matter.

  3. What inputs typically drive novelty and obviousness critiques?
    Cited prior art, examiner rejections, and claim limitations that distinguish over specific references.

  4. What parts of a patent define protection strength in litigation?
    Independent claim scope, limiting dependent claims, and how the specification supports and constrains interpreted claim terms.

  5. Can analysis proceed using only the patent number?
    Not under the constraints here because the needed claim text and record details are not included in the prompt.


References

No sources were cited because no claim text, bibliographic record, or prior-art/prosecution details were provided in the prompt.

More… ↓

⤷  Start Trial

Details for Patent 5,849,704

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Novo Nordisk Inc. NORDITROPIN somatropin Injection 021148 June 20, 2000 5,849,704 2015-06-02
Novo Nordisk Inc. NORDITROPIN somatropin Injection 021148 October 01, 2004 5,849,704 2015-06-02
Novo Nordisk Inc. NORDITROPIN somatropin Injection 021148 March 10, 2009 5,849,704 2015-06-02
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.